Background: There has been a push toward implementation of electronic health records (EHRs) in federally-funded hospitals under the current policies initiated by the Indian government, with a lack of evidence supporting their adoption. We analyzed data from the American College of Cardiology's PINNACLE (Practice Innovation and Clinical Excellence) India Quality Improvement Program (PIQIP) to evaluate the association between EHR use and quality of cardiovascular disease care in India. Methods and Results: Between 2011-2016, we collected data on performance measures for patients with coronary artery disease (CAD), heart failure (HF) and atrial fibrillation (AF) among 17 participating practices in PIQIP. There were 19,035 patients with CAD, 9,373 patients with HF, and 1,127 patients with AF. Documentation of co-morbidity burden in patients with CAD was lower among practices with EHR-hypertension (49.8% vs. 52.1%, p = 0.003), diabetes (34.9% vs. 38.3%, p < 0.001), and hyperlipidemia (0.2 vs. 3.9%, p < 0.001). On the contrary, documentation of medication prescription was higher in CAD patients seen at practices with EHR-aspirin (63.2% vs. 17.8%, p < 0.001), clopidogrel (41.7% vs. 27.4%, p < 0.001), beta-blockers (61.4% vs. 9.8%, p < 0.001), and ACE-i or ARBs (53.9% vs. 16.4%, p < 0.001). Similarly, documentation of receipt of beta-blockers (43.8% vs. 10.7%, p < 0.001), ACE-i or ARBs (40.8% vs. 16.1%, p < 0.001), and beta-blockers + ACE-i or ARBs (36.4% vs. 3.6%, p < 0.001) was also significantly higher in patients with HF seen at practices with EHR. Among patients with AF, documentation of oral anticoagulation use was significantly higher among EHR practices-warfarin (42.5% vs. 26.1%, p < 0.001). Conclusions: Documentation of receipt of guideline-directed medical therapy in CAD, HF, and AF was significantly higher in practices with EHRs in India compared with sites without EHRs. Our findings shed a spotlight on the value of EHRs in future health care policy-making in India with regard to For HF patients, GDMT included prescription of beta-blockers, ACEi or ARBs, and the combination of beta-blockers + ACE-i or ARBs.
GDMT for AF included warfarin use. Data on GDMT for each condition represents use of medications by unique patients at any encounter during the study interval. We first assessed differences in baseline characteristics between patients seeking care in EHR versus non-EHR practices. Individual medication prescription for each of the disease states was compared between EHR and non-EHR practices. We then performed logistic regression analyses adjusting for patient's age, sex, practice location (urban vs. rural), history of hypertension or diabetes mellitus, and number of outpatient visits during the study interval to determine whether presence of EHR was independently associated with better documentation of quality. Data integrity was ensured by randomly sampling 25% OPD cards.
1 There were 19,035 patients with CAD (13,619 in EHR practices), 9373 patients with HF (8923 in EHR practices), and 1127 patients with AF (431 in EHR practices). Of the 17 practices, only 2 had fullyintegrated and operational EHRs. The mean age of the study population was 51.0 AE 17.6 years, and 67.1% were men. The mean number of encounters per patient were 2.7, with more encounters per patient in non-EHR practices compared with EHR practices (4.4 vs. 2.1). Documentation of co-morbidity burden in patients with CAD was lower among practices with EHR-hypertension (49.8% vs. 52.1%, p = 0.003), diabetes (34.9% vs. 38.3%, p < 0.001), and hyperlipidemia (0.2 vs. 3.9%, p < 0.001). On the contrary, documentation of medication prescription was higher in CAD patients seen at practices with EHR-aspirin (63.2% vs. 17.8%, p < 0.001), clopidogrel (41.7% vs. 27.4%, p < 0.001), beta-blockers (61.4% vs. 9.8%, p < 0.001), and ACE-i or ARBs (53.9% vs. 16.4%, p < 0.001). Similarly, documentation of receipt of beta-blockers (43.8% vs. 10.7%, p < 0.001), ACE-i or ARBs (40.8% vs.16.1%, p < 0.001), and beta-blockers + ACE-i or ARBs (36.4% vs. 3.6%, p < 0.001) was also significantly higher in patients with HF seen at practices with EHR. Among patients with AF, documentation of warfarin use was significantly higher among EHR practices -42.5% vs. 26.1%, p < 0.001 ( Our results indicate that the documentation of receipt of GDMT in CAD, HF, and AF was significantly higher in practices with EHR in India compared with sites without EHR. Study limitations include lack of data on medication contraindications that along with variable documentation practices in India may have impacted GDMT prescription. Our results cannot be entirely explained by better documentation because of EHR use, as baseline comorbidities were more frequently documented in practices with no EHR.
Our findings have implications in future health care policymaking in India with regard to widespread adoption of EHRs in primary and advanced specialty care OPDs in both public and private health care settings.
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